Sucampo Pharmaceuticals, Inc. : Sucampo Announces First Quarter 2012 Financial Results and Operating Highlights Teleconference and Webcast
05/02/2012| 04:20pm US/Eastern
Recommend:
Sucampo Pharmaceuticals, Inc. (NASDAQ: SCMP) today announced that it
will host a webcast and teleconference with senior management to discuss
its financial results and operating highlights for the first quarter
ended March 31, 2012, on Wednesday, May 9, 2012, at 5:00 pm Eastern. The
press release announcing the financial results and operating highlights
is expected to be released after the close of the capital markets that
day.
Investors interested in accessing the live audio webcast of the
teleconference may do so at http://investor.sucampo.com/phoenix.zhtml?c=201197&p=irol-calendar
and should log on 10 to 15 minutes before the teleconference begins in
order to download any software required. A replay of the webcast will
also be available on the Company's website for several days after the
live event. Alternatively, investors may dial 866-831-6267 or
1-617-213-8857 and use passcode 57549793. A replay of the teleconference
will be available by dialing 888-286-8010 or 1-617-801-6888, passcode
74158841, approximately two hours after the teleconference concludes.
The archive of the teleconference will remain available for 30 days.
About Sucampo Pharmaceuticals
Sucampo Pharmaceuticals, Inc., a global pharmaceutical company is
focused on the discovery, development and commercialization of
proprietary drugs based on prostones. The therapeutic potential of
prostones, which occur naturally in the human body as a result of
enzymic (15-PGDH) transformation of certain fatty acids, was first
identified by Ryuji Ueno, M.D., Ph.D., Ph.D., Sucampo Pharmaceuticals'
Chairman and Chief Executive Officer. Dr. Ueno founded Sucampo
Pharmaceuticals in 1996 with Sachiko Kuno, Ph.D., founding Chief
Executive Officer and currently Advisor, International Business
Development, and a member of the Board of Directors. For more
information, please visit www.sucampo.com.
Sucampo Forward-Looking Statements
This press release contains "forward-looking statements" as that term is
defined in the Private Securities Litigation Reform Act of 1995. These
statements are based on management's current expectations and involve
risks and uncertainties, which may cause results to differ materially
from those set forth in the statements. The forward-looking statements
may include statements regarding product development, product potential,
future financial and operating results, and other statements that are
not historical facts. The following factors, among others, could cause
actual results to differ from those set forth in the forward-looking
statements: the impact of pharmaceutical industry regulation and health
care legislation; Sucampo's ability to accurately predict future market
conditions; dependence on the effectiveness of Sucampo's patents and
other protections for innovative products; the risk of new and changing
regulation and health policies in the US and internationally and the
exposure to litigation and/or regulatory actions. No forward-looking
statement can be guaranteed and actual results may differ materially
from those projected. Sucampo undertakes no obligation to publicly
update any forward-looking statement, whether as a result of new
information, future events, or otherwise. Forward-looking statements in
this presentation should be evaluated together with the many
uncertainties that affect Sucampo's business, particularly those
mentioned in the risk factors and cautionary statements in Sucampo's
Form 10-K for the year ended Dec. 31, 2011, which the Company
incorporates by reference.
Sucampo Pharmaceuticals, Inc.
Kate de Santis, +1-240-223-3834
kdesantis@sucampo.com
© Business Wire 2012
Recommend :
